Biggest News Aggregation in the World
📰 Acticor Biotech News

Page 2 - Acticor Biotech News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Acticor Biotech. Real-time updates on events, politics, business and more.

ACTICOR Adapts Its ACTISAVE Clinical Study to Prepare the Registration of Glenzocimab for the Treatm

- Clinical results from ACTISAVE phase 2/3 study now expected in the second quarter of 2024- Optimised development plan to register glenzocimab in Europe and the United States projected no later than 2028PARIS--(BUSINESS WIRE)--Regulatory News:Acticor Biotech, (ISIN: FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical s...
United Kingdom United States France General Newton Biocapital Gilles Avenard European Medicines Agency

Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research

26.05.2023 - Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announces today that it will ...
Newton Biocapital Venture Investment Professor Steve Watson University Of Birmingham Scientific Committee French National Institute Of Health European Medicines Agency

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2023

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including
Newton Biocapital Regulation Of The French Financial Markets Authority French National Institute Of Health Venture Investment European Medicines Agency Regulatory News

DelveInsight Business Research, LLP: Acute Ischemic Stroke Market is Expected to Showcase Significant Growth at a CAGR of 10.6% During the Study Period (2019-2032), Predicts DelveInsight

The dynamics of the acute ischemic stroke (AIS) market are anticipated to change during the forecast period (2023-2032) owing to the improved knowledge of stroke pathophysiology, awareness of
United Kingdom United States Shruti Thakur Athersys Healios Asundexian Bayer Bristol Myers Squibb Janssen

ACTICOR BIOTECH: Availability of the 2022 Universal Registration Document and the preparatory documents for the combined general meeting of May 12, 2023

26.04.2023 - Regulatory News: ACTICOR BIOTECH (Paris:ALACT) (FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announces today the ...
France General United States Newton Biocapital French National Institute Of Health Venture Investment European Medicines Agency

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science